Research Interests
Jeff Coller is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University.
His lab has made seminal discoveries in the area of messenger RNA stability and translation. He received his Ph.D. in Cellular and Molecular Biology from the University of Wisconsin, and was a postdoctoral fellow in the Howard Hughes Medical Institute at the University of Arizona. Prior to moving to Johns Hopkins University, Dr. Coller served as Director of the RNA Center at Case Western Reserve University where he held the Henry Willson Payne Distinguished Professorship.
He studies the very essence of life: translation of the genetic code. His work has led to fundamental shifts in the understanding of gene expression by demonstrating that the genetic code is a major determinant of mRNA fate. He is the Co-founder of Tevard Biosciences and WyveRNA Therapeutics. In 2018, Tevard Biosciences was awarded Pfizer’s Golden Ticket award for promising neuroscience startups. His publications have been cited over 6,000 times, and he currently holds numerous patents for RNA-based therapeutic applications.
Titles
- Bloomberg Distinguished Professor, Biomedical Engineering
Education
- Postdoctoral training, Howard Hughes Medical Institute, University of Arizona, 2000-2005
- PhD, Cell and Molecular Biology, The University of Wisconsin – Madison, 1994-2000
- Hon. BS, Biology/Chemistry, The University of Michigan, 1990-1994
Recent Highlights
-
August 8, 2025Three Johns Hopkins experts discuss the potential of mRNA-powered therapeutics to produce lifesaving treatments and cures for a range of diseases, and why federal research cuts risk undermining U.S. scientific leadership in this emerging area.
-
June 23, 2025The Discovery Awards are intended to spark new interactions among investigators across the university rather than to support established projects.
-
March 20, 2025Federal funding for biomedical research pays off by enabling basic discoveries that lead to lifesaving treatments, writes Jeff Coller, whose lab is developing new ways to treat rare genetic diseases.